menu
    • menu

    Company profile for Abbisko Therapeutics

    NEW Drugs in Dev: 15
    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    Sharp is a leader in commercial packaging, clinical services, and sterile manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter), a subsidiary of Abbisko Cayman Limited (Stock Code: 2256.HK), today announced that it has entered into a worldwide collaboration and exclusive licensing agreement (the "Agreement") with Eli Lilly and Company ("Lilly") for the further discovery, development and potential commercialization of novel molecules against an undisclosed target for cardiometabolic disea...
    Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter), a subsidiary of Abbisko Cayman Limited (Stock Code: 2256.HK), today announced that it has entered into a worldwide collaboration and exclusive licensing agreement (the "Agreement") with Eli Lilly and Company ("Lilly") for the further discovery, development and potential commercialization of novel molecules against an undisclosed target for cardiometabolic diseases with critical unmet medical needs.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Abbisko TherapeuticsChina Flag
    Country
    Country
    China
    Address
    Address
    Building 3, Lane 898, Halei Road, Zhangjiang Hi-Tech Park, Shanghai, China
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.abbisko.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/abbisko/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/Abbisko2016

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Asia Pharma Expo

    Asia Pharma Expo

    Not Confirmed

    envelop Contact Supplier

    Asia Pharma Expo

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Abbisko NDA for Pimicotinib in TGCT Accepted by FDA
    Abbisko NDA for Pimicotinib in TGCT Accepted by FDA

    12 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/abbisko-therapeutics-announces-fda-acceptance-of-the-nda-for-pimicotinib-for-the-treatment-of-tenosynovial-giant-cell-tumor-302659104.html

    PR NEWSWIRE
    12 Jan 2026
    Share Share
    China's NMPA Approves Abbisko's Pimicotinib
    China's NMPA Approves Abbisko's Pimicotinib

    23 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/22/3209070/0/en/Abbisko-Therapeutics-CSF-1R-Inhibitor-Pimicotinib-Approved-by-the-China-NMPA-Addressing-the-Treatment-Gap-for-Tenosynovial-Giant-Cell-Tumor.html

    GLOBENEWSWIRE
    23 Dec 2025
    Share Share
    Pimicotinib Provides Long-Term Tumor Responses In TGCT Patients
    Pimicotinib Provides Long-Term Tumor Responses In TGCT Patients

    23 Oct 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/clinical-trials/pimicotinib-delivers-lasting-tumor-responses-and-sustained-symptom-relief-in-tgct-patients-18060

    INDPHARMAPOST
    23 Oct 2025
    Share Share
    Pimicotinib Shows Durable TGCT Response, Pain Improvement
    Pimicotinib Shows Durable TGCT Response, Pain Improvement

    17 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251017967416/en/Pimicotinib-Treatment-Demonstrates-Deep-and-Durable-Tumor-Responses-and-Continued-Improvements-in-Pain-and-Function-for-Patients-with-TGCT

    BUSINESSWIRE
    17 Oct 2025
    Share Share
    Abbisko Therapeutics Doses First Patient in Irpagratinib Study
    Abbisko Therapeutics Doses First Patient in Irpagratinib Study

    15 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/abbisko-therapeutics-completes-first-patient-dosing-in-registrational-study-of-irpagratinib-for-hcc-302481972.html

    PR NEWSWIRE
    15 Jun 2025
    Share Share
    Abbisko Therapeutics: China NMPA Accepts Pimicotinib NDA for TGCT
    Abbisko Therapeutics: China NMPA Accepts Pimicotinib NDA for TGCT

    10 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/abbisko-therapeutics-announces-china-nmpa-acceptance-of-new-drug-application-for-pimicotinib-for-the-treatment-of-tgct-302477057.html

    PR NEWSWIRE
    10 Jun 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search